Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,731 people get IMGN articles and Market Currents by email alert.
Get email alerts on IMGN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (May 3, 2013)
-
Business Wire (Apr 26, 2013)
-
Business Wire (Apr 18, 2013)
-
-
-
-
Business Wire (Apr 11, 2013)
-
-
-
-
Business Wire (Mar 12, 2013)
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Immunogen's T-DM1 Gets Presidential TreatmentOhad Hammer • Sun, Oct 3, 2010
-
-
The Rush to Buy ImmunoGenProhost Biotech • Fri, Mar 19, 2010
-
Time to Buy ImmunoGenBeta Delta • Thu, Dec 4, 2008
-
ImmunoGen's CEO Discusses F1Q13 Results - Earnings Call TranscriptFri, Oct 26, 2012 • 2 Comments
-
ImmunoGen's CEO Discusses F4Q12 Results - Earnings Call TranscriptFri, Aug 3, 2012
-
ImmunoGen CEO Discusses F1Q11 Results - Earnings Call TranscriptFri, Oct 29, 2010
-
ImmunoGen, Inc. F4Q10 (Qtr End 06/30/10) Earnings Call TranscriptWed, Aug 4, 2010
-
ImmunoGen, Inc. F3Q10 (Qtr End 03/31/10) Earnings Call TranscriptMon, May 3, 2010
-
ImmunoGen, Inc. F2Q10 (Qtr End 12/31/09) Earnings Call TranscriptFri, Jan 29, 2010
-
ImmunoGen, Inc. F3Q09 (Quarter End 03/31/09) Earnings Call TranscriptThu, Apr 30, 2009
-
ImmunoGen, Inc. F2Q09 (Qtr End 12/31/08) Earnings Call TranscriptTue, Feb 17, 2009
-
ImmunoGen, Inc. F1Q09, (Qtr End 9/30/08) Earnings Call TranscriptMon, Oct 27, 2008
-
ImmunoGen, Inc. F4Q08 (Qtr End 06/30/08) Earnings Call TranscriptMon, Sep 8, 2008
-
ImmunoGen Business Update Call TranscriptTue, Dec 11, 2007
-
Business Wire (May 3, 2013)
-
Business Wire (Apr 26, 2013)
-
Business Wire (Apr 18, 2013)
-
at CNBC.com (Apr 16, 2013)
-
Business Wire (Apr 11, 2013)
-
at CNBC.com (Apr 5, 2013)
-
at CNBC.com (Apr 4, 2013)
-
Business Wire (Mar 12, 2013)
-
Business Wire (Feb 22, 2013)
-
Business Wire (Feb 12, 2013)
-
Business Wire (Feb 5, 2013)
-
Business Wire (Jan 25, 2013)
-
Business Wire (Jan 18, 2013)
-
Business Wire (Jan 2, 2013)
-
Business Wire (Dec 19, 2012)
-
Business Wire (Dec 10, 2012)
-
Business Wire (Dec 6, 2012)
-
Business Wire (Dec 3, 2012)
-
Business Wire (Nov 26, 2012)
IMGN vs. ETF Alternatives
Company Description
We develop novel, targeted therapeutics for the treatment of cancer using our expertise in cancer biology, monoclonal antibodies, highly potent cytotoxic, or cell-killing, agents, and the design of linkers that enable these agents to be stably attached to the antibodies while in the blood stream... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, April 26, 6:31 AM Immunogen (IMGN): FQ3 EPS of -$0.02 beats by $0.12. Revenue of $25M beats by $13.06M. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
- Friday, April 26, 12:05 AM Notable earnings before Friday’s open: ABBV, AEP, AON, ARLP, B, BKW, BPO, COV, CVX, DHI, DLR, DTE, FLIR, GDI, GNC, GT, HMSY, IMGN, ITRI, LAZ, LYB, MPW, NOV, SPG, TRP, TYC, VFC, VTR, WETF, WY Comment! [Earnings]
- Thursday, April 25, 5:30 PM Notable earnings before Friday’s open: ABBV, AEP, AON, ARLP, B, BKW, BPO, COV, CVX, DHI, DLR, DTE, FLIR, GDI, GNC, GT, HMSY, IMGN, ITRI, LAZ, LYB, MPW, NOV, SPG, TRP, TYC, VFC, VTR, WETF, WY Comment! [Earnings]
- Wednesday, April 10, 8:36 AM Immunogen (IMGN) gets a lift early after saying preclinical studies show its antibody-drug conjugate is "highly active" against some over expressing cancer cells. IMGN says the skin cancer compound is "on track to become [its] fourth wholly owned clinical-stage" drug with trials to begin later this year. Shares +1.43% premarket. 2 Comments [Healthcare, On the Move]
- Thursday, April 4, 2:37 PM ImmunoGen (IMGN +1.8%) says it's amended its multi-target agreement with Novartis (NVS -0.6%), which was originally entered into in October, 2010. As a result, IMGN is eligible to receive a $1M upfront fee and the opportunity to receive milestone payments potentially totaling approximately $200M or $238M, depending on the composition of any resultant products. 1 Comment [Healthcare, On the Move]
- Friday, February 22, 10:27 AM More on ImmunoGen (IMGN): The stock's moving about quite a bit, but currently +3.8% following FDA approval of Kadcyla. The drug is being approved with a Boxed Warning alerting users and prescribers of heart and liver toxicity as well as severe life-threatening birth defects. 3 Comments [Healthcare, On the Move]
- Friday, February 22, 9:26 AM The FDA has approved ImmunoGen's (IMGN) breast cancer drug TDM1, now called Kadcyla. The approval triggers a $10.5M milestone payment to ImmunoGen, with royalties from sales to follow. Shares are halted. (PR) Comment! [Healthcare, Breaking News]
- Tuesday, February 12, 2:34 PM ImmunoGen (IMGN -1.2%) say's it's completed patient enrollment in the first stage of its NORTH two-stage Phase II trial assessing IMGN901, a first-line treatment candidate for small-cell lung cancer. Attaining this milestone enables the findings from the planned interim analysis at 6 months to be available in H213. Comment! [Healthcare]
- Monday, January 28, 2:52 PM ImmunoGen (IMGN -2.8%) slides after Oppenheimer cut the shares to Perform earlier today, saying that the success of its current breast cancer drug T-DM1 is now fully priced into the stock. As with the launch any drug launch, initial Street expectations are adjusted, and a post-launch pullback into low teens may be seen over the near term. Comment! [Healthcare, On the Move]
- Friday, January 25, 1:56 PM Shares of Immunogen (IMGN -2.4%) slip today after its FQ2 loss comes in wider than the analyst consensus. Revenue fell 65% Y/Y on an absence of milestone payments, while higher R&D costs hurt its bottom line. The company attributes the higher expenses to greater investment in advancing its wholly owned product candidates, increased clinical trial costs, and increased personnel expenses. The biotech firm maintained its FY13 guidance, calling for a net loss of $70M to $74M. Comment! [Healthcare, Earnings, On the Move]
- Friday, January 25, 6:37 AM Immunogen (IMGN): FQ2 EPS of -$0.29 misses by $0.04. Revenue of $2.6M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Friday, January 25, 12:05 AM Notable earnings before Friday’s open: AEP, COV, HAL, HON, IMGN, KMB, OSK, PG, WY Comment! [Earnings]
- Thursday, January 24, 5:30 PM Notable earnings before Friday’s open: AEP, COV, HAL, HON, IMGN, KMB, OSK, PG, WY Comment! [Earnings]
- Monday, January 14, 2:32 PM Investors interested in the prospects of young biotech companies might want to take a look at this Seeking Alpha article. It's a list of the upcoming FDA approval decision dates for Q1 2013, and with many of these developing firms having a good portion of their businesses riding on FDA approval decisions for their newly developed drugs, the stocks are likely to be sensitive to any positive or negative news over the near term. Comment! [Healthcare, Quick Ideas]
- Wednesday, December 19, 2012, 11:39 AM ImmunoGen (IMGN -0.5%) says that Amgen (AMGN -0.2%) has licensed the exclusive right to use the company's maytansinoid TAP technology to develop anticancer therapeutics to a third target, which is undisclosed. For each license, IMGN receives a $1M upfront payment and is entitled to receive milestone payments potentially totaling $34M plus royalties on the sales of any resulting products. AMGN is responsible for the development, manufacturing and marketing of any products resulting from the license. Comment! [Healthcare]
- Monday, December 10, 2012, 5:58 PM ImmunoGen (IMGN) presents new clinical data on it's targeted anticancer compound, IMGN901, saying that - in cases where it was evaluated as single-agent therapy – the evidence supports further development of the drug as a treatment for CD56-expressing cancers. Shares +0.3% AH. Comment! [Healthcare]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES